Evaluation of PAI-039 [{1-Benzyl-5-[4-(trifluoromethoxy)phenyl]-1H-indol-3- yl}(oxo)acetic Acid], a novel plasminogen activator inhibitor-1 inhibitor, in a canine model of coronary artery thrombosis

Journal of Pharmacology and Experimental Therapeutics

Volumn 314, Issue 2, 2005, Pages 710-716

  Hennan, James K ^a   Elokdah, Hassan ^a   Leal, Mauricio ^a   Ji, Allena ^a   Friedrichs, Gregory S ^a,b   Morgan, Gwen A ^a   Swillo, Robert E ^a   Antrilli, Thomas M ^a   Hreha, Amy ^a   Crandall, David L ^a  

^a PFIZER INC   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; BENZYL 5 [4 (TRIFLUOROMETHOXY)PHENYL] 1H INDOL 3 YL}(OXO)ACETIC ACID]; PAI 039; PLASMINOGEN ACTIVATOR INHIBITOR 1; UNCLASSIFIED DRUG;

ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BLOOD CLOT LYSIS; BLOOD CLOTTING; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY THROMBOSIS; DOG; DRUG BIOAVAILABILITY; ELECTROLYSIS; EX VIVO STUDY; FIBRINOLYSIS; HEART INFARCTION; INCIDENCE; MALE; NONHUMAN; PLASMA HALF LIFE; PRIORITY JOURNAL; PROTHROMBIN TIME; REPERFUSION; THROMBOCYTE AGGREGATION;

ACETIC ACIDS; ANIMALS; BLEEDING TIME; BLOOD PRESSURE; CORONARY CIRCULATION; CORONARY THROMBOSIS; DOGS; ENDPOINT DETERMINATION; FIBRINOLYSIS; FIBRINOLYTIC AGENTS; HEART RATE; HEMOSTASIS; INDOLEACETIC ACIDS; INDOLES; PARTIAL THROMBOPLASTIN TIME; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET AGGREGATION; VENTRICULAR REMODELING;

EID: 22944431859     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.105.084129     Document Type: Article

References (33)

1. Armstrong PW and Collen D (2001) Fibrinolysis for acute myocardial infarction: current status and new horizons for pharmacological reperfusion, part 1. Circulation 103:2862-2866.
2. Biemond BJ, Levi M, Coronel R, Janse MJ, Ten Cate JW, and Pannekoek H (1996) Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis. Circulation 91:1175-1181.
3. Bjork I, Ylinenjarv K, Olson ST, and Bock PE (1992) Conversion of antithrombin from an inhibitor of thrombin to a substrate with reduced heparin affinity and enhanced conformational stability by binding of a tetradecapeptide corresponding to the P1 to P14 region of the putative reactive bond loop of the inhibitor. J Biol Chem 267:1976-1982.
4. Carmeliet P, Stassen JM, Schoonjans L, Ream B, van den Oord JJ, De Mol M, Mulligan RC, and Collen D (1993) Plasminogen activator inhibitor-1 gene-deficient mice: effects on hemostasis, thrombosis and thrombolysis. J Clin Investig 92: 2756-2760.
5. Chandler WL, Alessi MC, Aillaud MF, Henderson P, Vague P, and Juhan-Vague I (1997) Clearance of tissue plasminogen activator (TPA) and TPA/plasminogen activator inhibitor type 1 (PAI-1) complex. Circulation 96:761-768.
6. Cook JJ, Gardell SJ, Holahan MA, Sitko GR, Stump GL, Wallace AA, Gilberto DB, Hare TR, Krueger JA, Dyer DL, et al. (1999) Antithrombotic efficacy of thrombin inhibitor L-374,087: intravenous activity in a primate model of venous thrombus extension and oral activity in a canine model of primary venous and coronary artery thrombosis. J Pharmacol Exp Ther 289:503-510.
7. Crandall DL, Elokdah H, Di L, Hennan JK, Gorlatova NV, and Lawrence DA (2004) Characterization and comparative evaluation of a structurally unique PAI-1 inhibitor exhibiting oral in-vivo efficacy. J Thromb Haemost 2:1422-1428.
8. Eitzman DT, Westrick RJ, Xu Z, Tyson J, and Ginsburg D (2000) Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery. Blood 96:4212-4215.
9. Elokdah H, Abou-Gharbia M, Hennan JK, McFarlane G, Mugford CP, Krishnamurthy G, and Crandall DL (2004) Tiplaxtinin, a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1: design, synthesis and preclinical characterization. J Med Chem 47:3491-3494.
10. Farrehi PM, Ozaki CK, Carmeliet P, and Fay WP (1998) Regulation of arterial thrombolysis by plasminogen activator inhibitor-1 in mice. Circulation 97:1002-1008.
11. Festa A, D'Agostino R Jr, Tracy RP, and Haffner SM (2002) Insulin Resistance Atherosclerosis Study. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 51:1131-1137.
12. Gils A and Declerck PJ (2004) The structural basis for the pathophysiological relevance of PAI-I in cardiovascular diseases and the development of potential PAI-I inhibitors. Thromb Haemost 91:425-437.
13. Hrafnkelsdottir T, Gudnason T, Wall U, Jern C, and Jern S (2004) Regulation of local availability of active tissue-type plasminogen activator in vivo in man. J Thromb Haemost 2:1960-1968.
14. Juhan-Vague I, Alessi MC, Mavri A, and Morange PE (2003) Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost 1:1575-1579.
15. Lawrence DA (1997) The serpin-proteinase complex revealed. Nat Struct Biol 4:339-341.
16. Lawrence DA and Loskutoff DJ (1986) Inactivation of plasminogen activator inhibitor by oxidants. Biochemistry 25:6351-6355.
17. Lisman T, de Groot P, Meijers C, and Rosendaal F (2005) Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood 105:1102-1105.
18. Ma LJ, Mao SL, Taylor KL, Kanjanabuch T, Guan Y, Zhang Y, Brown NJ, Swift LL, McGuinness OP, Wasserman DH, et al. (2004) Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 53:336-346.
19. Matsuno H, Kozawa, Okada K, Ueshima S, Matsuo O, and Uematsu T (2002) Inhibitors of fibrinolytic components play different roles in the formation and removal of arterial thrombus in mice. J Cardiovasc Pharmacol 39:278-286.
20. Mickelson JK, Simpson PJ, and Lucchesi BR (1989) Antiplatelet monoclonal F(ab′)2 antibody directed against the platelet GPIIb/IIIa receptor complex prevents coronary artery thrombosis in the canine heart. J Mol Cell Cardiol 21:393-405.
21. Nicholls SC, Hoffer EK, and Chandler WL (2003) Failure of peripheral arterial thrombolysis due to elevated plasminogen activator inhibitor type 1. Blood Coagul Fibrinolysis 14:729-733.
22. Potempa J, Korzus E, and Travis J (1994) The serpin superfamily of proteinase inhibitors: structure, function and regulation. J Biol Chem 269:15957-15960.
23. Potter van Loon BJ, Rijken DC, Brommer EJ, and van der Maas AP (1992) The amount of plasminogen, tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in human thrombi and the relation to ex-vivo lysibility. Thromb Haemost 67:101-105.
24. Robbie LA, Bennett B, Keyt BA, and Booth NA (2000) Effective lysis of model thrombi by a t-PA mutant (A473S) that is resistant to alpha2-antiplasmin. Br J Haematol 111:517-523.
25. Sobel BE, Taatjes DJ, and Schneider DJ (2003) Intramural plasminogen activator inhibitor type-1 and coronary atherosclerosis. Arterioscler Thromb Vasc Biol 23: 1979-1989.
26. Stefansson S, McMahon GA, Petitclerc E, and Lawrence DA (2003) Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling. Curr Pharm Des 9:1545-1564.
27. Stringer HA, van Swieten P, Heijnen HF, Sixma JJ, and Pannekoek H (1994) Plasminogen activator inhibitor-1 released from activated platelets plays a key role in thrombolysis resistance. Studies with thrombi generated in the Chandler loop. Arterioscler Thromb 14:1452-1458.
28. van Giezen JJ, Wahlund G, Nerme V, and Abrahamsson T (1997) The Fab-fragment of a PAI-1 inhibiting antibody reduces thrombus size and restores blood flow in a rat model of arterial thrombosis. Thromb Haemost 77:964-969.
29. Verstraete M (1998) Thrombolysis in the management of lower limb peripheral arterial occlusion-a consensus document. Working Party on Thrombolysis in the Management of Limb Ischemia. Am J Cardiol 81:207-218.
30. Wang H, Yu A, Wiman B, and Pap S (2003) Identification of amino acids in antiplasmin involved in its noncovalent lysine-binding-site-dependent interaction with plasmin. Eur J Biochem 270:2023-2029.
31. Wiman B and Collen D (1977) Purification and characterization of human antiplasmin, the fast-acting plasmin inhibitor in plasma. Eur J Biochem 78:19-26.
32. Wu Q and Zhao Z (2002) Inhibition of PAI-1: a new antithrombotic approach. Curr Drug Targets Cardiovasc Haematol Disord 2:27-42.
33. Zhu Y, Carmeliet P, and Fay WP (1999) Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance. Circulation 99:3050-3055.